Articles > Insulins & Non-insulins

Insulin Singled Out in Ambitious Bill By House Democrats to Lower Drug Prices

The bill would mandate that the government negotiate with drug makers about the price of insulin, both in the Medicare program and for the open insurance market. It also includes many other mechanisms intended to lower the price of insulin and other drugs.

Children with High Genetic Risk for Type 1 Diabetes Have Distinct Gut Microbiomes When Compared to Those at Lower Risk

An examination of 403 biological samples reveals that some gut bacteria was absent in children at higher risk of developing type 1 diabetes.

Eylea, a Treatment for Diabetic Retinopathy, Now Available in Prefilled Syringes

The drug is just one of two on the market currently approved specifically to treat the diabetes-related eye condition, among other eye ailments.

ere are Six Recent Moves to Curb Co-Pay Costs for Insulin

Four insurers have introduced a cap on monthly insulin costs, but the federal government’s move to change regulations around high-deductible insurance plans may have the biggest long-term impact.

The company also will offer a $99 monthly subscription for up to three vials or two packs of any combination of Novo Nordisk’s analog insulins.

JDRF Announces the Creation of its First Center for Excellence

The inaugural Northern California Center for Excellence will bring together key diabetes researchers investigators involved in diabetes cellular therapy and immune system research from Stanford University and UCSF.

Insulin Pumps for Beginners

Insulin Pumps for Beginners

An overview of insulin pump therapy, with Diabetes Care and Education Specialist Ashlee Ernst.

Semma Therapeutics, Which is Developing Beta Cell Replacement Therapy, to Be Purchased for $950 Million

Vertex Pharmaceuticals announced it will acquire the company, which is developing this innovative cellular therapy to treat type 1 diabetes.

Fiasp Approved for Children with Type 1 Diabetes in Europe

Novo Nordisk, the makers of Fiasp, has also asked the FDA to approve pediatric use of the insulin.

Two Minnesota Insurers Move to Cap or Eliminate Out-of-Pocket Insulin Costs

Blue Cross Blue Shield of Minnesota will eliminate out-of-pocket costs for its fully insured customers, while UCare will cap the costs at $25 a month.